We are live on ! Find out more
LGND icon

Ligand Pharmaceuticals

322.75 USD
+5.42
1.71%
At close Updated Oct 30, 4:00 PM EDT
Pre-market
After hours
324.00
+1.25
0.39%
1 day
1.71%
5 days
6.03%
1 month
3.32%
3 months
8.93%
6 months
40.66%
Year to date
69.77%
1 year
72.54%
5 years
241.53%
10 years
440.44%
 

About: Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.

Employees: 47

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 18.8%
Neutral 81.3%
Negative 0%
Neutral
Seeking Alpha
18 hours ago
Ligand Pharmaceuticals Incorporated (LGND) Q3 2026 Earnings Call Transcript
Ligand Pharmaceuticals Incorporated ( LGND ) Q3 2026 Earnings Call October 29, 2026 8:30 AM EDT Company Participants Melanie Herman - Executive Director of Investor Relations and Financial Planning & Analysis Todd Davis - CEO & Director Octavio Espinoza - Chief Financial Officer Lauren Hay Paul Hadden - Senior Vice President of Investments & Business Development Conference Call Participants Matthew Hewitt - Craig-Hallum Capital Group LLC, Research Division David Risinger - Leerink Partners LLC, Research Division Glen Santangelo Annabel Samimy - Stifel, Nicolaus & Company, Incorporated, Research Division Yigal Nochomovitz - Citigroup Inc., Research Division Leland Gershell - Oppenheimer & Co. Inc., Research Division Sahil Dhingra - RBC Capital Markets, Research Division Presentation Operator Hello, everyone. Thank you for joining us, and welcome to the Ligand Third Quarter Earnings Call.
Ligand Pharmaceuticals Incorporated (LGND) Q3 2026 Earnings Call Transcript
Neutral
MarketBeat
1 day ago
What Ligand Pharmaceuticals (LGND) Said on Its Q3 Earnings Call
Ligand Pharmaceuticals NASDAQ: LGND reported third-quarter royalty revenue growth of 51% year over year to approximately $70 million, driven by Filspari, Ohtuvayre and commercial assets acquired through its July purchase of XOMA Royalty. The company also raised its full-year adjusted diluted earnings-per-share outlook while maintaining its revenue guidance.
What Ligand Pharmaceuticals (LGND) Said on Its Q3 Earnings Call
Neutral
GlobeNewsWire
1 day ago
Ligand Reports Third Quarter 2026 Financial Results
Third-quarter royalty revenue up  51% year-over-year to $70.3 million Raises Full-Year 2026 Adjusted Diluted EPS Guidance to $9.50 to $9.75, from $9.00 to $9.50 1 ; Reaffirms Revenue Guidance Conference call begins at 8:30 a.m. Eastern Time today JUPITER, Fla.
Ligand Reports Third Quarter 2026 Financial Results
Neutral
GlobeNewsWire
3 days ago
Ligand to Participate in November Investor Conferences
JUPITER, Fla., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its senior management team will participate in the following upcoming investor conferences: UBS Global Healthcare Conference.
Ligand to Participate in November Investor Conferences
Neutral
GlobeNewsWire
8 days ago
Ligand to Host Investor Day on December 8, 2026
Ligand to Host Investor Day on December 8, 2026
Neutral
GlobeNewsWire
15 days ago
Ligand to Report Third Quarter 2026 Financial Results on October 29, 2026
JUPITER, Fla., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report third quarter 2026 financial results on Thursday, October 29, 2026.
Ligand to Report Third Quarter 2026 Financial Results on October 29, 2026
Neutral
GlobeNewsWire
1 month ago
Ligand and AvenCell Therapeutics Enter Financing Agreement to Advance Pipeline of Next-Generation CAR-T Therapies for Up to $47 Million
JUPITER, Fla., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it has entered into a financing agreement with AvenCell Therapeutics, Inc., a clinical-stage cell therapy company developing controllable, allogeneic CAR-T therapies for patients with cancer, for up to $47 million.
Ligand and AvenCell Therapeutics Enter Financing Agreement to Advance Pipeline of Next-Generation CAR-T Therapies for Up to $47 Million
Neutral
Business Wire
1 month ago
Sydnexis Announces Royalty Agreement with Ligand for Ryjunea®
DEL MAR, Calif.--(BUSINESS WIRE)--Sydnexis, Inc., a biopharmaceutical company focused on developing a novel low-dose atropine formulation to treat pediatric progressive myopia (PPM), today announced an agreement with Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) to sell its royalty rights associated with net sales of Ryjunea® in Europe, the Middle East, and Africa (EMEA). Under the terms of the agreement, Ligand will pay $23 million upfront to acquire a 100% interest in certain payments an.
Sydnexis Announces Royalty Agreement with Ligand for Ryjunea®
Neutral
PRNewsWire
1 month ago
Primrose Bio® Raises Significant Growth Capital Investment Led by Signet Healthcare Partners
SAN DIEGO, Sept. 22, 2026 /PRNewswire/ -- Primrose Bio, Inc. ("Primrose"), a provider of production solutions for next-generation biologics, today announced the closing of a financing round led by new investor Signet Healthcare Partners ("Signet"), with significant participation from existing investors 1315 Capital, Ligand Pharmaceuticals Incorporated (Nasdaq: LGND), LDV Partners, and Agent Capital.
Primrose Bio® Raises Significant Growth Capital Investment Led by Signet Healthcare Partners
Neutral
GlobeNewsWire
1 month ago
Ligand Acquires Royalty and Milestone Interest in Santen's Ryjunea® from Sydnexis for $23 Million
Ryjunea is the first and only pharmacologic treatment approved by the European Commission and UK MHRA to slow myopia progression in pediatric patients Ligand will receive a tiered low-double-digit to high-teens royalty on Ryjunea net sales in Europe, the Middle East, and Africa JUPITER, Fla., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced it has acquired an ascending tiered royalty interest in Santen Pharmaceutical Co., Ltd.
Ligand Acquires Royalty and Milestone Interest in Santen's Ryjunea® from Sydnexis for $23 Million
Price charts implemented using Lightweight Charts™